Healthy AdultsNCT07416786
Validation of NAD+ Measurements for Human Clinical Studies
A study testing Oral NR Supplementation in people with Healthy Adults, run by University of Pennsylvania at 1 site in United States.
Trial summary
The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS). Read more about this study
- Who is it for?
- Ages 18 to 110 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Adults
- What is being tested?
- Oral NR Supplementation
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2026to 31 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 110 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
- Male or female age18-35 years or 70 years or older, healthy
- if female reproductive potential, use of highly effective contraception (at least 1 month prior to screening and during study participation).
- No known sensitivity to NR
- No use of niacin, blood thinners or chemotherapy agents
- HbA1c below 8.5% and not diabetec requiring insulin.
- Not using/taking corticosteroids
- No laboratory abnormalities indicating significant anemia, bleeding risk, kidney disease, or liver disease
- No contraindication to MRI
- Not Pregnant, lactating, or planning to become pregnant during participation
- Not taking multivitamins or any over-the-counter supplements except calcium and vitamin D (any other supplements - discontinued 2 weeks prior to study participation).
- not taking/ undergoing another investigational drug or other intervention within the past 30 days.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Penn Medicine
Philadelphia, Pennsylvania, 19104-6006
Mark Elliott, Ph.D, 215-898-8648, melliott@upenn.edu
Damodar Reddy, 215-898-9357, cdamodar@pennmedicine.upenn.edu
About this study
Official title: Validation of NAD+ Measurements for Human Clinical Studies: Multi-method Inter-laboratory Standardization
The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).
Read the detailed description
This is an open-label, nonrandomized study, primary outcome is to correlate blood and tissue measurements of NAD+ and metabolites. Investigators will recruit 12 men and 12 women aged 18-35 years and 12 men/12 women aged 70 years or older. Whole blood, serum and urine will be collected and MRS measurements performed at baseline and 30 days for in vivo determinations of nicotinamide adenine dinucleotide (NAD) and its metabolites. After baseline measurements, participants will take 1000 mcg of NR orally daily for 30 days. Baseline measurements will be repeated on days 29 and 30. Assessors of outcomes will be blinded to study status of participants.
- Conditions
- Healthy Adults
- Being tested
- Oral NR Supplementation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral NR SupplementationDietary supplement
Oral Nicotinamide Riboside (NR)
| Study group | Role | What they receive |
|---|---|---|
| NR Arm | Experimental | All participants will receive NR 1000mg capsules to take by mouth daily for approximately 30 days. Receives: Dietary Supplement: Oral NR Supplementation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Nicotinamide adenine dinucleotide (NAD) measurement in brain MRI
NAD level will be assessed in brain MRI
Measured: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
NAD measurement of calf MRI
NAD level in calf MRI
Measured: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
Secondary outcomes (2)
Serum NAD metabolites
Measurement of serum metabolites of Nicotinamide adenine dinucleotide
Measured: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with NR
Urine NAD metabolites
Measurement of urine NAD metabolites
Measured: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start1 Sep 2026
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AdultsStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- 2 age groups, both to corrrelate blood and tissue measurements of NAD+ and metabolites.
- Masking
- None (open label)
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Sponsor
- Investigators
- Ravinder Reddy, Ph.D., Principal investigator, University of PennsylvaniaJoseph A. Baur, Ph.D., Study director, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07416786
- Sponsor's protocol ID
- IRB 859875
- Other IDs
- U01AG089107-02
- Status last verified
- Sep 2026
- First submitted
- 16 Jan 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of NAD+ Measurements for Human Clinical Studies: Multi-method Inter-laboratory Standardization
- ClinicalTrials.gov ID
- NCT07416786
- Acronym / sponsor ID
- IRB 859875
- Conditions
- Healthy Adults
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- 1 Sep 2026 (actual)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).
Detailed description
This is an open-label, nonrandomized study, primary outcome is to correlate blood and tissue measurements of NAD+ and metabolites. Investigators will recruit 12 men and 12 women aged 18-35 years and 12 men/12 women aged 70 years or older. Whole blood, serum and urine will be collected and MRS measurements performed at baseline and 30 days for in vivo determinations of nicotinamide adenine dinucleotide (NAD) and its metabolites. After baseline measurements, participants will take 1000 mcg of NR orally daily for 30 days. Baseline measurements will be repeated on days 29 and 30. Assessors of outcomes will be blinded to study status of participants.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- 2 age groups, both to corrrelate blood and tissue measurements of NAD+ and metabolites.
| Arm | Type | Receives |
|---|---|---|
| NR Arm | Experimental | Dietary Supplement: Oral NR SupplementationAll participants will receive NR 1000mg capsules to take by mouth daily for approximately 30 days. |
Who may qualify
- Ages
- 18 to 110 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral NR SupplementationOral Nicotinamide Riboside (NR) | Dietary supplement | NR Arm |
Primary outcome
Nicotinamide adenine dinucleotide (NAD) measurement in brain MRI
Time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
NAD level will be assessed in brain MRI
NAD measurement of calf MRI
Time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
NAD level in calf MRI
2 secondary outcomes
Serum NAD metabolites
Time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with NR
Urine NAD metabolites
Time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Adults
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ravinder Reddy, Ph.D. principal investigator
University of Pennsylvania
Joseph A. Baur, Ph.D. study director
University of Pennsylvania
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Oral NR Supplementation in people with Healthy Adults, run by University of Pennsylvania at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Damodar Reddy (215-898-9357, cdamodar@pennmedicine.upenn.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Nicotinamide adenine dinucleotide (NAD) measurement in brain MRI (time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.